2014 Program Schedule

2014 PROGRAM IN DEVELOPMENT

Available in July with Session and Speaker Schedules. See Highlights on First Announcement.

 
Tuesday, November 4
Early Registration

Wednesday, November 5
Hematologic , GI , Pediatric Oncology
 
Thursday, November 6
GNY, Head And Neck, Thyroid, CNS, Breast
 
Friday, November 7
Prostate, Renal, Bladder, Ling, Sarcomas, Immuno-Oncology
 
 

EMERGING DEVELOPMENTS

  Advances In Immuno-Oncology Based Therapies
  Albumin-Binding Drug Conjugates
  DNA-Based Diagnostic Systems
  Genetic Bridges To Selective Therapies
  Gene Sequencing
  Harnessing The Immune System
  Metabolic Activity In Solid Tumors
  Molecular Diagnostic Modalities
  Mutations and Treatment Change
  New Generation Delivery Systems
  Patient-Derived Tumor Cells
  Targeting Cancer-Killer Cells
  Tracking Tumor Markers
  Twenty First Century Vanguards

HIGHLIGHTS OF MULTI-SPECIALTY SESSIONS

  HEMATOLOGY
  AML, ALL, CLL, Lymphomas, Myelodysplastic Diseases, Novel Agents and Targets, Vaccines, Pediatric Cancers in Adulthood and Differential Mutations
   
  GI CANCERS
  CRC, Pancreatic, Gastic, Biliary
  21ST Century Screening and Therapy
  DNA-Based Diagnosis
  Reducing Recurrence-Risk with Exercise
   
  GYNECOLOGICAL CANCERS
  Patient-Derived Tumor Cells
  Ovarian Trial Endpoints
  PARP Inhibitors
  Endometrial Therapy Updated
  The BASKET Trials
  BRCA Carriers
   
  BREAST CANCER
  The MicroEnvironment
  ER Mutations and Resistance
  Adjuvant Endocrine Therapy
  SERDS: Estrogen Receptor Degraders
  Immune Checkpoint Blockaders
   
  GENITOURINARY: Prostate, Renal, Bladder
  Hormone Sensitivity
  Neuroendocrine Differentiation
  Targeting the Androgen Pathway
  Genetic-Related Treatment Concepts
  Limiting Treatment-Related Morbidity
  New Agents in Metastatic Disease
   
  THYROID CANCER 
  New Clinical Trial Data
   
  LUNG CANCER 
  Genomic Tools
  Activating New Targets
  Novel AntiTumor Active Agents
   
  SARCOMAS 
  Clinical Trials Results
  Albumin as a Targeting Agent
   
  IMMUNOLOGY 
  Natural Tumor-Killer Cells
   
  PEDIATRIC ONCOLOGY 
  Advances in Therapy of Children and Young Adults
   
  CNS 
  Treating Glioblastoma

Register Now

 

We are pleased to acknowledge the contributions of the Tisch Cancer Institute to the development of the Symposium program.